Results 251 to 260 of about 37,898 (281)

Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF

ESC Heart Failure, 2022
The angiotensin receptor‐neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val) demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all‐cause mortality in patients with ambulatory heart failure and reduced ...
V. Visco, I. Radano, A. Campanile, A. Ravera, A. Silverio, D. Masarone, G. Pacileo, M. Correale, P. Mazzeo, G. Dattilo, F. Giallauria, A. Cuomo, V. Mercurio, C. Tocchetti, P. Di Pietro, A. Carrizzo, R. Citro, G. Galasso, C. Vecchione, M. Ciccarelli   +19 more
semanticscholar   +1 more source

The value of C‐reactive protein‐to‐albumin ratio in predicting long‐term mortality among HFrEF patients with implantable cardiac defibrillators

European Journal of Clinical Investigation, 2021
Patients with heart failure with reduced ejection fraction (HFrEF) who received implantable cardiac defibrillator (ICD) still remain at high risk due to pump failure and prevalent comorbid conditions.
G. Çinier, M. Hayıroğlu, Z. Kolak, O. Tezen, A. Yumurtaş, L. Pay, S. Eren, T. Çetin, S. Özcan, Ceyhan Türkkan, Nazmiye Özbilgin, A. Tekkeşin, A. Alper, K. Gürkan   +13 more
semanticscholar   +1 more source

Prognostic nutritional index as the predictor of long‐term mortality among HFrEF patients with ICD

Pacing and clinical electrophysiology : PACE, 2021
The benefit of implantable cardiac defibrillator (ICD) in patients with heart failure and reduced ejection fraction (HFrEF) could be limited in a particular group of patients.
G. Çinier, M. Hayıroğlu, L. Pay, A. Yumurtaş, O. Tezen, S. Eren, Z. Kolak, T. Çetin, S. Özcan, Ceyhan Türkkan, Nazmiye Özbilgin, A. Tekkeşin, A. Alper, K. Gürkan   +13 more
semanticscholar   +1 more source

Angiogenesis Markers and Reverse Remodeling in Patients With HFrEF

Journal of Cardiac Failure, 2023
No abstract ...
Assad, Noma, Mebazaa, Alexandre, Azibani, Feriel   +2 more
openaire   +3 more sources

Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease

Current Medical Research and Opinion, 2021
Objective To compare the effects of Angiotensin Receptor-Neprilysin inhibitor (ARNI) on the clinical symptoms, echocardiographic parameters, and outcomes (cardiovascular death and hospitalization) in heart failure with reduced ejection fraction (HFrEF ...
D. Raphael, Zhiyu Liu, Zhi Jin, Xinyue Cui, Dongjian Han, Weiwei He, Jiahong Shangguan, Deliang Shen   +7 more
semanticscholar   +1 more source

Co-morbidity (HFrEF and HFpEF): hypertension

2019
Hypertensive heart disease is a major cause of heart failure (HF) and mortality. Hypertension precedes HF occurrence in 75% of cases, and carries a sixfold increase in HF risk as compared to non-hypertensive individuals. Most importantly, a minority of patients survive 5 years after the onset of hypertensive HF.
Francesco Paneni, Massimo Volpe
openaire   +1 more source

HFrEF pharmacological treatment: beta blockers

2018
By incremental steps over several decades of research, beta blockers have evolved ‘from bench to bedside’, emerging as a keystone of modern optimal pharmacotherapy for heart failure. This chapter starts by detailing the story of their development, focusing on the randomized trials that established their clinical efficacy in reducing hospitalization and
Simon Beggs, Roy S Gardner
openaire   +2 more sources

HFrEF pharmacological treatment: ivabradine

2018
Ivabradine slows down the heart rate through a blockade of the funny current channels in the sinoatrial node cells. The efficacy of the drug was tested in a large outcome clinical trial in stable chronic heart failure with reduced ejection fraction, in sinus rhythm, on a contemporary background therapy including beta blockers.
openaire   +2 more sources

Skeletal muscle alterations in HFrEF vs. HFpEF

Current Heart Failure Reports, 2017
Severe exercise intolerance and early fatigue are hallmarks of heart failure patients either with a reduced (HFrEF) or a still preserved (HFpEF) ejection fraction. This review, therefore, will provide a contemporary summary of the alterations currently known to occur in the skeletal muscles of both HFrEF and HFpEF, and provide some further directions ...
Axel Linke, Ephraim B. Winzer, Volker Adams   +2 more
openaire   +3 more sources

Definition, epidemiology, and burden of disease: HFrEF

2018
Heart failure is the final common stage of many diseases of the heart, caused by structural and/or functional cardiac abnormalities, resulting in a reduced cardiac output. The clinical profile of patients with heart failure with reduced ejection fraction (HFrEF) is generally more severe than that of patients with heart failure and preserved ejection ...
Aldo Pietro Maggioni, Ovidiu Chioncel
openaire   +2 more sources